Upcoming CME Events
-
Atlantic Regional Hematopathology Meeting Future Directions of Hematopathology Advances in hematopathology, as well as in molecular and genetic information, are evolving at a rapid rate. However, it is difficult to remain current with the latest advances, let alone interpret their meaning and applicability to diagnosis and therapy. This meeting will focus on the “Future Directions of Hematopathology” with emphasis on the role of molecular pathology and new technologies in the diagnosis, prognostic stratification and treatment of challenging cases. Participants will be asked to incorporate advances in molecular and genetic information indicators/markers and test results in order to enhance interpretation of complex cases.
Complimentary registration for all participants; includes breakfast, lunch, coffee breaks and program
CME Registration Deadline: Wednesday, May 17, 2023
Details
Saturday, May 20, 2023
8:30AM–3:00 pm EST Exhibit Hall OpenFox Chase Cancer Center Auditorium
333 Cottman Avenue
Philadelphia, PA 19111Intended Audience
Hematopathologists, pathologists of other subspecialties, hematologists/oncologists, radiation oncologists, internists, primary care providers, fellows and residents of pathology, oncology and other specialties
Inquiries
Lucía Tono, PhD, MEd: 215-728-3797
Lucia.Tono-Ramirez@tuhs.temple.eduPresenters
Keynote Speakers
Jeffrey Medeiros, MD
Professor & Chairman, Department of Hematopathology, MD Anderson Cancer CenterMariusz Wasik, MD
Professor & Chair of Pathology; Associate Director of Cancer Center; DE&S Morel, S&S Bayster Chair in Molecular Diagnosis, Fox Chase Cancer CenterProgram Director
Reza Nejati, MD
Associate Professor; Director, Flow Cytometry Lab; Medical Director of TUH-FCCC Clinical Laboratories; Department of Pathology, Fox Chase Cancer CenterPlanning Committee Members
Mariusz Wasik, MD
Professor & Chair of Pathology; Associate Director of Cancer Center; DE&S Morel, S&S Bayster Chair in Molecular Diagnosis, Fox Chase Cancer CenteryNicholas Mackrides, MD
Assistant Professor, Department of Pathology, Fox Chase Cancer CenterTahseen I. Al-Saleem, MD
Professor Emeritus, Department of Pathology, Fox Chase Cancer CenterHenry C. Fung, MD, FACP, FRCPE
Vice-Chair, Department of Hematology/Oncology; Chief, Section of Hematologic Malignancies; Director, Fox Chase – Temple University Hospital; BMT Program, Fox Chase Cancer CenterSubmission of Abstracts
We invite you to submit abstracts of clinical, scientific, and educational value with a focus on the role of molecular pathology and new technologies in the diagnosis, prognostic stratification and treatment of challenging cases.
To submit an abstract for consideration, please send the following by Monday, April 3, 2023 to Lucia.Tono-Ramirez@tuhs.temple.edu:
- 1-page abstract, case description and diagnosis in a Word document (NO SLIDES)
- In the abstract, please specify the name, credential, affiliation and email of the person presenting the case if selected for oral presentation
Notification of cases selected will be via email.
If you are selected for ORAL PRESENTATION, please follow these instructions:
- Presentations consist of a 15-minute lecture
- You will receive an email from "eeds" (the CME software) requesting you to upload the following by Monday, May 8, 2023:
- Set of PowerPoint slides with a brief patient history and a couple of pictures to post on the eeds site prior to the event for reference—please abstain from providing a diagnosis or any discussion. Please title your slides as follow: “Presenter’s last name, first initial-WITH DIAGNOSIS-Title”
- Electronic copy of your PowerPoint slides as you will present them. Please title your slides as follow: “Presenter’s last name, first initial-WITH DIAGNOSIS-Title”
- Speaker disclosure of the person presenting the case
If you are selected for POSTER EXHIBIT, please follow these instructions:
- Poster exhibits will be displayed all day and can be presented during breaks.
- Please bring a hard copy of your poster on the day of the event
- 4'x6' poster boards with stands will be available
Learning Objectives
After attending this program, participants should be able to:
At the end of this activity, participants should be able to:
- Recognize the indicators/markers and test results to look for in complex cases to aid in diagnosis
- When appropriate, incorporate recent molecular immunophenotypic and genetic information when interpreting results, determining diagnoses and selecting therapies
- Discuss the latest advances related to the characteristics of progression in B-cell lymphomas
Accreditation Statement
The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.
Certification Statement
The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity
-
21st Annual Highlights of the 2022 San Antonio Breast Cancer Symposium Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this virtual CME is designed to help medical, radiation, and surgical oncologists, gynecologists, radiologists, and primary care physicians translate the data from key presentations from the 2022 San Antonio Breast Cancer Symposium into practice.
Join speakers from Fox Chase and Penn Medicine’s Abramson Cancer Center as they present information on the treatment of breast cancer, including screening, prevention, local control, chemotherapy, hormonal therapy, and advances in breast cancer biologic and their impact on breast cancer management.
Details
VIRTUAL CME: Thursday, January 19, 2023
5:00–9:00 pm EST Exhibit Hall Open
6:00–8:30 pm EST Education Program
8:30–9:00 pm EST Virtual Q&A Reception & Exhibit HallInquiries
Lucía Tono, PhD, MEd: 215-728-3797
Lucia.Tono-Ramirez@tuhs.temple.eduPresenters
Program Director
Lori J. Goldstein, MD, FASCO
Professor Emerita, Department of Hematology/Oncology, Fox Chase Cancer CenterFox Chase Cancer Center Faculty
Richard J. Bleicher, MD, FACS
Professor, Department of Surgical Oncology; Leader, Breast Cancer Program; Director, Breast Fellowship ProgramMelissa McShane, MD
Assistant Professor, Department of Hematology/Oncology; Associate Program Director, Hematology/Oncology Fellowship Training ProgramSaba Shaikh, MD
Assistant Professor, Department of Hematology/OncologyPenn Medicine's Abramson Cancer Center Faculty
Susan M. Domchek, MD
Executive Director, Basser Center for BRCA; Director, MacDonald Cancer Risk Evaluation Center; Basser Professor in OncologyAngela DeMichele, MD, MSCE
Jill & Alan Miller Endowed Chair in Breast Cancer Excellence; Professor of Medicine; Co-Leader, Breast Cancer Program; Co-Director, 2-PREVENT Translational Center of ExcellenceLearning Objectives
After attending this program, participants should be able to:
- Analyze the advances in the management of breast cancer and premalignant breast disease and, when clinically relevant, integrate new findings into the management of patients with breast cancer and premalignant breast disease.
- When clinically relevant, apply new strategies for optimizing existing treatments into the management of these patients.
- Analyze new developments in breast cancer research and current available clinical trials and, when clinically relevant, include this information in discussions with patients.
Intended Audience
The program is designed for medical, radiation, and surgical oncologists, gynecologists, radiologists, and primary care physicians. Other physician specialties, nurses, advanced practice clinicians, and healthcare professionals involved in the treatment of patients with breast cancer may find the program beneficial.
Accreditation Statement
The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.
Designation Statement
The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity
-
On-Demand 20th Annual Highlights of the 2021 San Antonio Breast Cancer Symposium
It is the policy of the Temple Health Office for Continuing Medical Education to ensure that all sponsored continuing medical education activities are independently designed and produced and include content that is valid, objective, balanced, free of commercial bias and in the best interest to the public. Temple Health policy requires everyone in a position to control the content of an educational activity to disclose all financial relationships with ineligible companies and to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Temple Health Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to the activity.